In today's VETgirl online veterinary continuing education podcast, we review the cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs. If you're using pro-BNP to help differentiate pulmonary versus cardiac disease, you need to pay attention. Congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) in dogs is relatively common and yet generally carries a poor long-term prognosis with current standard medical therapies [e.g., diuretics, angiotensin converting enzyme (ACE) inhibitors, and pimobendan]. Additional therapies remain a topic of investigation. The body's natural diuretic system revolves around the natriuretic peptides, including brain natriuretic peptide (BNP1-32). BNP1-32 causes diuresis, natriuresis, vasodilation, and inhibits the renin-angiotensin-aldosterone system (RAAS) via binding to natriuretic peptide receptor A (NPR-A) and greater production of cyclic guanosine monophosphate (cGMP).